It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Aneurysm Prevention Study

Clinical Trial Title: 
Estrogen Therapy as Prevention in the Progression of Aneurysm
Clinical Trial Protocol ID: 
12101906
Clinical Trial Investigator Name: 
Michael Chen, MD
Clinical Trial Protocol Description: 

This is a prospective, randomized, placebo-control trial to test the effect of estradiol in the prevention of progression of cerebral aneurysms. To evaluate the effect, each subject will be treated with either oral estradiol or placebo for six months. Subjects will be randomly assigned to one of two groups, as follows:

  • Double Blind Treatment Group Open-Label Regimen
    • A1 1 mg Estradiol daily for 180 days
    • B1 Placebo for 180 days

Each group will be given oral progesterone (3300 mg) for 10 days at the end of 90 days regardless of menstrual pattern. Subjects will be asked to keep a menstrual calendar throughout the trial. Serum markers will be drawn at baseline and every 90 days with the results blinded until the end of the trial. Magnetic resonance angiography (MRA) studies of the brain will be performed at month 6.

Clinical Trial Eligibility Criteria: 

You may be eligible to participate in this study if you:

  • Are a generally healthy female
  • Are 40-52 years of age
  • Have had at least one documented saccular intracranial cerebral aneurysm detected via catheter angiography/magnetic resonance angiography/computed tomography angiography

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.

Clinical Trial Area: 
Stroke and Cerebrovascular Disease
Women's Health
Contact Phone: 
(312) 563-2817
Contact Name: 
Michael Chen, MD